Shareholders elect Rosa, approve reverse stock split and 2025 equity plan at annual meeting.

NEUROONE MEDICAL TECHNOLOGIES Corp

David Rosa elected Class II director: 11,724,206 for, 381,677 against, 6,011,755 broker non-votes.
Baker Tilly U.S., LLP ratified as auditor: 18,080,780 for, 7,381 against, 29,477 abstain.
Reverse stock split approved (ratio 1-for-2 to 1-for-15): 16,176,833 for, 1,732,603 against.
2025 Equity Incentive Plan approved: 10,595,402 for, 1,473,888 against, 6,010,237 broker non-votes.
Adjournment authorization approved: 16,811,725 for, 1,270,013 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.